2024 - RAS Dialogue Blog
-
Therapeutic strategies to overcome KRAS (OFF) inhibitors resistanceUnderstanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. In a new blog post, Drs. Mira and Nokin describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein. They observed an increase in active GTP-loaded KRAS in patient samples, and argue for the dual inhibition of both active and inactive KRAS as a more effective therapeutic strategy.
-
MAP2K4: New kid on the MAP Kinase blockPost-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.
-
-
Development of Mutant KRAS Molecuar Target Drugs and Future Prospects: ReportIn a new post, Drs. Fuyuhiko Tamanoi, Hideyuki Saya, Toshio Imai, and Kiyoko Kato present a report of the online meeting that they organized, titled “Development of mutant KRAS molecular target drugs and future prospects.”
-
Senescent macrophages promote oncogenic KRAS-driven lung cancer and suppress anti-tumour immunityDrs. Haston, Muñoz-Espin, and Martinez-Barbera describe their work uncovering the important role that senescent macrophages play in promoting KRAS-driven lung cancers.